Please use this identifier to cite or link to this item:
|Title:||Antimony and bismuth compounds in oncology|
|Citation:||Tiekink, E.R.T. (2002). Antimony and bismuth compounds in oncology. Critical Reviews in Oncology/Hematology 42 (3) : 217-224. ScholarBank@NUS Repository. https://doi.org/10.1016/S1040-8428(01)00217-7|
|Abstract:||The main group elements antimony and bismuth are used clinically, primarily for the treatment of Leishmaniasis (antimony) and ulcers (bismuth). Despite their medicinal efficacy, the exploration of the anti-cancer potential of antimony and bismuth compounds is not as well developed as for other metal-containing species. The results of cytotoxicity and anti-tumour screening for antimony(III), antimony(V) and bismuth(III) compounds are summarised in this review. While this is a relatively undeveloped field of research endeavour, promising anti-tumour activity has been reported, in particular for bismuth compounds. © 2002 Elsevier Science Ireland Ltd. All rights reserved.|
|Source Title:||Critical Reviews in Oncology/Hematology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Aug 10, 2018
WEB OF SCIENCETM
checked on Jul 16, 2018
checked on May 25, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.